Psychiatry · Mood Disorders
The facts most likely to be tested
Postpartum depression is defined as a major depressive episode occurring within four weeks to twelve months postpartum.
The Edinburgh Postnatal Depression Scale (EPDS) or Patient Health Questionnaire-9 (PHQ-9) are the standard screening tools used during postpartum visits.
Postpartum depression is distinguished from postpartum blues by the presence of functional impairment, suicidal ideation, or symptoms lasting longer than two weeks.
Selective serotonin reuptake inhibitors (SSRIs), specifically sertraline, are the first-line pharmacotherapy due to their favorable safety profile during lactation.
Psychotherapy, particularly cognitive behavioral therapy (CBT) or interpersonal therapy (IPT), is the initial treatment of choice for mild to moderate postpartum depression.
Brexanolone is a GABA-A receptor positive allosteric modulator indicated for the treatment of severe postpartum depression.
A history of prior postpartum depression or major depressive disorder is the strongest risk factor for the development of postpartum depression.
Vignette unlocked
A 28-year-old G1P1 female presents for her 6-week postpartum checkup. She reports feeling overwhelmed, insomnia despite the infant sleeping, and a loss of interest in activities she previously enjoyed. She denies auditory hallucinations or thoughts of harming the infant, but admits to feeling worthless and having difficulty bonding with her newborn. She is currently breastfeeding and has no prior psychiatric history.
What is the most appropriate first-line pharmacologic treatment for this patient?
Sertraline
The patient meets the criteria for postpartum depression, and SSRIs like sertraline are the first-line treatment of choice due to their minimal excretion into breast milk.
Full handout
High yield triage
Etiology / Epidemiology
Occurs within 4 weeks postpartum; prior history of depression is the strongest risk factor.
Clinical Manifestations
Persistent anhedonia and depressed mood; baby blues resolve by day 10, PPD persists >2 weeks.
Diagnosis
Clinical diagnosis using DSM-5 criteria; use the Edinburgh Postnatal Depression Scale for screening.
Treatment
SSRIs are first-line; do not breastfeed with certain medications if contraindicated.
Prognosis
High risk of recurrence in future pregnancies; untreated PPD leads to impaired mother-infant bonding.
Full handout
Epidemiology & Etiology
PPD affects 10-15% of postpartum women, typically presenting within the first 4 weeks after delivery. Major risk factors include a history of major depressive disorder, lack of social support, and socioeconomic stressors. It is distinct from the transient maternity blues which typically peak at day 5 and resolve by day 10.
Pertinent Anatomy
The hypothalamic-pituitary-adrenal (HPA) axis is the primary neuroanatomical system involved. Rapid postpartum fluctuations in estrogen and progesterone levels impact neurotransmitter sensitivity in the limbic system. Dysregulation of these pathways directly correlates with the severity of mood symptoms.
Pathophysiology
The rapid withdrawal of placental hormones triggers a neurobiological vulnerability in susceptible individuals. This leads to altered serotonin and norepinephrine signaling within the brain. Chronic sleep deprivation and the physical stress of childbirth act as catalysts for the onset of the depressive syndrome.
Clinical Manifestations
Patients present with anhedonia, sleep disturbances, and feelings of worthlessness. Unlike postpartum psychosis, which features delusions or hallucinations and is a psychiatric emergency, PPD involves persistent sadness. Red flags include suicidal ideation or thoughts of harming the infant, requiring immediate inpatient evaluation.
Diagnosis
Diagnosis is based on DSM-5 criteria requiring symptoms for at least 2 weeks. The Edinburgh Postnatal Depression Scale is the gold-standard screening tool used in clinical practice. A score of >10-13 typically warrants a formal diagnostic interview to confirm the condition.
Treatment
Sertraline is the first-line pharmacotherapy due to its safety profile during lactation. Psychotherapy, specifically Cognitive Behavioral Therapy (CBT), is highly effective as an adjunct or monotherapy for mild cases. Brexanolone is an FDA-approved infusion for severe cases, though it requires strict monitoring for excessive sedation.
Prognosis
Untreated PPD significantly impairs mother-infant bonding and child developmental outcomes. There is a 30-50% risk of recurrence in subsequent pregnancies. Close monitoring is required to prevent progression to chronic depression or suicide.
Differential Diagnosis
Postpartum Blues: self-limiting, resolves within 10 days
Postpartum Psychosis: presence of hallucinations or delusions
Thyroiditis: check TSH to rule out postpartum thyroid dysfunction
Adjustment Disorder: symptoms related to a specific stressor without meeting MDD criteria
Bipolar Disorder: history of manic or hypomanic episodes